KR102700008B1 - 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법 - Google Patents

티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법 Download PDF

Info

Publication number
KR102700008B1
KR102700008B1 KR1020237007117A KR20237007117A KR102700008B1 KR 102700008 B1 KR102700008 B1 KR 102700008B1 KR 1020237007117 A KR1020237007117 A KR 1020237007117A KR 20237007117 A KR20237007117 A KR 20237007117A KR 102700008 B1 KR102700008 B1 KR 102700008B1
Authority
KR
South Korea
Prior art keywords
compound
peaks
diffraction pattern
inhibitors
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237007117A
Other languages
English (en)
Korean (ko)
Other versions
KR20230035692A (ko
Inventor
케이티 알렉산더
존 씨. 주니어 아메디오
셀추크 칼림시즈
마이클 가이에르
제랄딘 씨. 해리만
시준 후
존 피. 로슨
헨리 모리슨
카일 사보우린
마크 이. 스콧
비말 바르게세
쿠날 아르빈드 바리아
샤오티안 왕
샤오웨이 양
Original Assignee
길리어드 아폴로, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리어드 아폴로, 엘엘씨 filed Critical 길리어드 아폴로, 엘엘씨
Priority to KR1020247028256A priority Critical patent/KR102744343B1/ko
Publication of KR20230035692A publication Critical patent/KR20230035692A/ko
Application granted granted Critical
Publication of KR102700008B1 publication Critical patent/KR102700008B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
KR1020237007117A 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법 Active KR102700008B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247028256A KR102744343B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662302755P 2016-03-02 2016-03-02
US62/302,755 2016-03-02
US201662303237P 2016-03-03 2016-03-03
US62/303,237 2016-03-03
PCT/US2017/020271 WO2017151816A1 (en) 2016-03-02 2017-03-01 Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
KR1020187027295A KR102622161B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187027295A Division KR102622161B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028256A Division KR102744343B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Publications (2)

Publication Number Publication Date
KR20230035692A KR20230035692A (ko) 2023-03-14
KR102700008B1 true KR102700008B1 (ko) 2024-08-29

Family

ID=58347936

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237007117A Active KR102700008B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
KR1020247028256A Active KR102744343B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
KR1020187027295A Active KR102622161B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247028256A Active KR102744343B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
KR1020187027295A Active KR102622161B1 (ko) 2016-03-02 2017-03-01 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법

Country Status (15)

Country Link
US (4) US10183951B2 (enExample)
EP (2) EP4364795A3 (enExample)
JP (3) JP6944462B2 (enExample)
KR (3) KR102700008B1 (enExample)
CN (3) CN108699078A (enExample)
AU (3) AU2017226267B2 (enExample)
BR (1) BR112018067408A2 (enExample)
CA (4) CA3155220C (enExample)
ES (1) ES2972487T3 (enExample)
IL (1) IL261255A (enExample)
MX (1) MX2018010427A (enExample)
PL (1) PL3423456T3 (enExample)
SG (1) SG11201807077RA (enExample)
TW (3) TWI818828B (enExample)
WO (1) WO2017151816A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CA3137479A1 (en) 2017-03-03 2018-09-07 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
WO2019015583A1 (en) * 2017-07-17 2019-01-24 Nanjing Ruijie Pharmatech Co., Ltd. NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS
KR20190036705A (ko) * 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
CN111182904A (zh) 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
CN112574253B (zh) * 2019-09-29 2021-08-27 上海喀露蓝科技有限公司 磷酸或磷酸酯类衍生物、其制备方法及其在医药上的用途
CN110746439B (zh) * 2019-10-18 2020-10-30 南京瑞捷医药科技有限公司 一种噻吩并嘧啶二酮化合物的制备方法
CN112778325A (zh) * 2019-11-07 2021-05-11 南京瑞捷医药科技有限公司 一种acc抑制剂及其用途
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CN114787166B (zh) * 2019-12-05 2023-09-19 漳州片仔癀药业股份有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
WO2021110135A1 (zh) * 2019-12-05 2021-06-10 漳州片仔癀药业股份有限公司 作为acc1和acc2抑制剂的晶型及其制备方法和应用
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en) 2020-04-02 2025-05-21 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
ES3061522T3 (en) 2021-03-29 2026-04-06 Gilead Sciences Inc Khk inhibitors
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
KR102337422B1 (ko) 2021-07-27 2021-12-08 (주)최금실 호호바오일을 포함하는 피부진정 및 트러블 개선용 화장료 조성물 및 이의 제조방법
KR102309616B1 (ko) 2021-07-27 2021-10-05 최금실 호호바오일을 포함하는 피부 재생 및 피부 보습용 화장료 조성물 및 이의 제조방법
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN115785066B (zh) 2022-12-08 2024-05-31 广东工业大学 曲格列汀晶型f及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123231A1 (en) 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670560A (en) 1986-04-28 1987-06-02 Ortho Pharmaceutical Corporation Thienopyrimidine-2,4-dione derivatives and intermediates thereof
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
TW276256B (enExample) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JP3811196B2 (ja) 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
JPH09110873A (ja) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd チエノピリミジン誘導体、その製造法および用途
AU6670196A (en) 1995-08-17 1997-03-12 Takeda Chemical Industries Ltd. Thienopyrimidine derivatives, their production and use
AU2407997A (en) 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
JP2007302703A (ja) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd 医薬組成物
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
MXPA03004926A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas.
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
ES2324472T3 (es) 2003-01-06 2009-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Herbicidas que inhiben la accion de acetil-coa carboxilasa en vegetales para su uso como pesticidas.
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
WO2006014647A2 (en) 2004-07-21 2006-02-09 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
EP2151440A4 (en) 2007-05-21 2010-10-20 Takeda Pharmaceutical Heterocyclic compound and use thereof
WO2009155611A1 (en) 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
PT2519527E (pt) 2009-12-29 2014-02-17 Poxel Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
WO2013123231A1 (en) 2012-02-15 2013-08-22 Robert Bosch Gmbh Pressure sensor with doped electrode
JP5842804B2 (ja) * 2012-12-28 2016-01-13 カシオ計算機株式会社 表示端末装置及びプログラム
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
MX2017008844A (es) 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
PL3380479T3 (pl) * 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
US20170166582A1 (en) * 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
AU2018209006B2 (en) 2017-01-22 2021-04-22 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
KR20190036705A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
US12323113B2 (en) 2021-11-29 2025-06-03 Macom Technology Solutions Holdings, Inc. Circuit and method of shutdown for bias network in high voltage amplifier

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123231A1 (en) 2011-11-11 2013-05-16 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2015007451A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Also Published As

Publication number Publication date
US20170267690A1 (en) 2017-09-21
WO2017151816A1 (en) 2017-09-08
JP7356564B2 (ja) 2023-10-04
AU2023206094A1 (en) 2023-08-10
US11912718B2 (en) 2024-02-27
TWI788281B (zh) 2023-01-01
SG11201807077RA (en) 2018-09-27
TWI818828B (zh) 2023-10-11
JP2019507160A (ja) 2019-03-14
CA3220447C (en) 2025-08-05
EP3423456A1 (en) 2019-01-09
CN119977993A (zh) 2025-05-13
JP2021185206A (ja) 2021-12-09
MX2018010427A (es) 2019-03-06
EP3423456B1 (en) 2023-12-27
PL3423456T3 (pl) 2024-06-17
TW202330543A (zh) 2023-08-01
KR20180114937A (ko) 2018-10-19
BR112018067408A2 (pt) 2018-12-26
CA3015526C (en) 2022-10-04
CA3220447A1 (en) 2017-09-08
US20200148699A1 (en) 2020-05-14
JP7184988B2 (ja) 2022-12-06
AU2021209149B2 (en) 2023-04-20
AU2023206094B2 (en) 2025-09-04
AU2021209149A1 (en) 2021-08-19
CN112920200A (zh) 2021-06-08
TW202400605A (zh) 2024-01-01
US11104687B2 (en) 2021-08-31
KR20230035692A (ko) 2023-03-14
US10183951B2 (en) 2019-01-22
TWI844474B (zh) 2024-06-01
KR20240131478A (ko) 2024-08-30
CA3172549C (en) 2026-03-24
US10487090B2 (en) 2019-11-26
CA3172549A1 (en) 2017-09-08
CA3155220C (en) 2024-01-16
AU2017226267A1 (en) 2018-09-06
US20220064181A1 (en) 2022-03-03
CA3155220A1 (en) 2017-09-08
KR102744343B1 (ko) 2024-12-18
AU2017226267B2 (en) 2021-06-24
JP2023010977A (ja) 2023-01-20
EP4364795A2 (en) 2024-05-08
IL261255A (en) 2018-10-31
CN108699078A (zh) 2018-10-23
ES2972487T3 (es) 2024-06-13
JP6944462B2 (ja) 2021-10-06
EP4364795A3 (en) 2024-08-14
KR102622161B1 (ko) 2024-01-09
TW201738247A (zh) 2017-11-01
EP3423456C0 (en) 2023-12-27
CA3015526A1 (en) 2017-09-08
US20190225623A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP7184988B2 (ja) チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法
HK40110261A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40002905A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40002905B (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40055242A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40125827A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601